FDA Brief

Warning letters Drugs

FDA warning letter to

Fancystage Unipessoal, LDA

High riskIssued Aug 3, 2023Posted Aug 8, 2023Center for Drug Evaluation and Research | CDER

Portugal OTC drug maker Fancystage Unipessoal skipped identity testing of high-risk ingredients and lacked quality-unit control, FDA says.

What happened

FDA reviewed records and other information the company submitted after a March 17, 2023 request for records under section 704(a)(4) of the FD&C Act; this was a records review, not an inspection. The records showed the firm did not test each shipment of each lot of incoming components at high risk of hazardous-impurity contamination to confirm identity, and that its quality unit did not effectively approve or reject components. FDA placed the firm on Import Alert 66-40 on May 8, 2023.

What FDA found

  1. The company did not perform at least one identity test on each incoming shipment of each lot of components, including components at high risk of carrying hazardous impurities that have caused lethal poisonings worldwide.

    21 CFR 211.84(d)(1)
  2. The quality unit was not given or did not use its authority to approve or reject components, containers, closures, in-process materials, packaging, labeling, and finished drugs.

    21 CFR 211.22(a)

What FDA wants

FDA tells the company to respond in writing within 30 working days describing corrections, and to send impurity test results on retained high-risk component lots or implicated finished batches within 30 calendar days, plus a risk assessment, recalls if needed, and a quality-unit remediation plan. FDA also recommends hiring a qualified CGMP consultant to do a six-system audit before resuming U.S. manufacturing.

Who should pay attention

  • brands and distributors that buy OTC drugs made by this contract manufacturer
  • U.S. importers and own-label sellers of children's OTC drug products
  • suppliers and buyers relying on certificates of analysis for high-risk raw materials

This is a summary. Read the original letter on fda.gov.

Fancystage Unipessoal, LDA's FDA history

  1. Fancystage Unipessoal, LDA

    FDA warned Portugal OTC drug maker Fancystage Unipessoal of repeated CGMP failures, untested ingredients, unvalidated processes and misbranded fluoride mouthwash.

    High risk

Full company page

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Conroe Welding Supply, Inc.

    FDA warns Conroe Welding Supply over medical oxygen manufacturing failures, including untested batches and a container with 99% (b)(4).

    High risk
  3. Sanrace Biotechnology Co., Ltd.

    FDA warns Sanrace Biotechnology over CGMP failures in OTC drugs, including missing identity tests and no process validation.

    High risk
  4. TSP Solutions Pte. Ltd.

    FDA warns Singapore OTC drug maker TSP Solutions over missing release testing and component identity checks for sunscreens.

    High risk